Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC503 (UCAR-T) in Relapsed/Refractory Multiple Myeloma
NCT07139509Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UC503 in multiple myeloma (MM). Primary endpoints: Incidence rate of UCAR-T-related adverse events and Incidence rate of Dose limited toxicity at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
UC503
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07139509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139509.